Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Afternoon workouts may beat morning exercise for blood sugar control

NCT ID NCT05123963

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether exercising in the afternoon is better than the morning for improving blood sugar control in people with prediabetes. 48 participants will do high-intensity interval training three times a week for 12 weeks. Researchers will measure how the body stores and uses fat and sugar to see if timing makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-intensity interval training (HIIT) on a cycle ergometer
What this could lead to
If it works, this could show that simply changing when you exercise can improve blood sugar control and reduce the risk of type 2 diabetes.
What could go wrong
This is a small, early-phase study with only 48 people. The results may not apply to everyone, and it's possible that exercise timing makes little difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pre-diabetes: * Fasting plasma glucose: 6.1 to 6.9 mmol/L or * 2-hour plasma glucose post 75g OGTT: 7.8 to 11.0 mmol/L and * HbA1c: 6.0 to 6.4% * or Insulin resistant: glucose clearance rate ≤ 360 ml/kg/min as determined using the Oral Glucose Insulin Sensitivity Index at Time 120 min. * BMI \> 25 kg/m2 * To be willing and able to adhere to the specifications of the protocol; * To have signed an informed consent document indicating that they understood the purpose of and procedures required for the study and were willing to participate in the study. Exclusion Criteria: * overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG * Treatment with any drug known to affect lipid or carbohydrate metabolism, except statins (to be stopped 3 weeks prior to study A), metformin or anti-hypertensive drugs (to be stopped 7 days prior to the studies); * presence of liver or renal disease other than uncomplicated NASH or mild isolated proteinuria; uncontrolled thyroid disorder; * Uncontrolled severe hypertension, systolic pressure ≥ 180 mm Hg or diastolic pressure ≥ 110 mm Hg; * History of ischemic heart disease, tachyarrhythmia, QT interval prolongation, risk factors for torsade de pointes (eg hypokalemia), or taking any medication known to prolong the QT interval; * History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux requiring surgery, etc.); * Presence of a pacemaker; * Having undergone a PET study or CT scan in the past year; * Any contraindication to stopping statins for 3 months and stopping an anti-hypertensive medication and metformin for 7 days; * smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day; * No blood donation two month prior the study; * prior history or current fasting plasma cholesterol level \> 7 mmol/l or fasting TG \> 6 mmol/l.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetic state are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre de recherche du CHUS

    RECRUITING

    Sherbrooke, Quebec, J1H 5N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.